JPMorgan upgraded IGM Biosciences (IGMS) to Neutral from Underweight without a price target The firm says that with the company announcing ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...

IGM Biosciences (NASDAQ:IGMS) lost nearly two-thirds of its value on Friday after the company abandoned two antibody-based ...

The therapeutic candidate is a bi-specific T cell engager IgM antibody targeting CD20 and CD3. It is being developed based on IgM antibody technology. The drug candidate was also under the development ...

The therapeutic candidate is a bi-specific T cell engager IgM antibody targeting CD20 and CD3. It is being developed based on IgM antibody technology. The drug candidate was also under the development ...

We are also exploring modifications to the assay for detecting serotype-specific IgM antibodies indicative of a recent infection. Although our study is foundational for further development and ...

SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical ...

Additionally, the antibody proved “consistent across subgroups” and appeared well tolerated in both IBD conditions with no safety signals identified, according to the partners. Overall rates ...

This helps support our journalism. Learn more. Please also consider subscribing to WIRED Normally, antibodies are protective proteins produced by our immune systems to fight bacteria or viruses.